ACCESS Newswire·Jul 31, 2026, 8:30 AM ET

DataMeds AI's Corexa Pharmacy Launches Tollo Health's Tollovid(R) and Galactovid(TM)

MEDS

DataMeds AI, Inc. (NASDAQ: MEDS) announced direct-to-consumer distribution of Tollovid® and Galactovid™ through its subsidiary Corexa Pharmacy starting July 31, 2026.
Tollovid® is a dietary supplement designed to support immune function by inhibiting 3CL protease activity associated with SARS-CoV-2.
Galactovid™ is a medical food formulated to manage viral infections linked to galectin-1 and galectin-3, including SARS-CoV-2, Herpes Simplex Virus-1, and Influenza A.
Products are marketed by Tollo Health, LLC, which has entered a distribution arrangement with Corexa Health for pharmacist-supported channels.
DataMeds AI has signed a letter of intent to acquire a controlling interest in Tollo Health, subject to definitive agreements and customary closing conditions.
Interim Co-CEO Gerald E. Commissiong cited the Long COVID treatment market's expected growth from $3.2 billion in 2023 to over $32.8 billion in 2031 as a key driver.
The company attributes market growth to new protocols combining biopharmaceutical drugs with supplements, increased awareness of Long COVID, & improved diagnostic tools.
Corexa Health pharmacists are trained to assist patients with the appropriate use of these products available via www.CorexaRx.com/Store.
DataMeds AI utilizes its EinsteinRx™ AI platform & PharmacyChain™ blockchain platform to support its integrated Health IT & pharmacy solutions.
Forward-looking statements in the release highlight risks regarding the potential acquisition completion, regulatory classification of supplements, & technology integration challenges.